| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185179 | Gynecologic Oncology | 2014 | 7 Pages |
Abstract
Neratinib may be a potential treatment option for patients harboring HER2/neu amplified USC. Clinical trials for this subset of endometrial cancer patients are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Carlton L. Schwab, Diana P. English, Dana M. Roque, Stefania Bellone, Salvatore Lopez, Emiliano Cocco, Roberta Nicoletti, Thomas J. Rutherford, Peter E. Schwartz, Alessandro D. Santin,